US 12291571
Methods for reducing eosinophilic infiltration by administering an anti-interleukin-4 receptor (IL4R) antibody
granted A61KA61K2039/505A61K2039/54
Quick answer
US patent 12291571 (Methods for reducing eosinophilic infiltration by administering an anti-interleukin-4 receptor (IL4R) antibody) held by REGENERON PHARMACEUTICALS, INC. expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 27
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K2039/577